TEAD

Choose Selective TEAD Inhibitors
Isoform-selective Inhibitors

TEAD Products

  • All (7)
  • TEAD Inhibitors (6)
  • New TEAD Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8164 YAP-TEAD Inhibitor 1 (Peptide 17) YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.
PLoS One, 2022, 17(4):e0266143
Research (Wash D C), 2022, 2022:9825916
Cancer Res, 2021, 81(22):5652-5665
S8554 Super-TDU Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.
Nat Commun, 2022, 13(1):3117
Int J Mol Med, 2022, 49(6)84
J Exp Clin Cancer Res, 2021, 40(1):23
S8661 CA3 (CIL56) CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS).
Cell Rep, 2022, 38(7):110390
Sci Rep, 2022, 12(1):45
Int J Ophthalmol, 2022, 15(5):701-710
S8950 MYF-01-37 MYF-01-37 is a novel covalent inhibitor of TEAD targeting Cys380 when incubated with the TEAD2 protein.
S8951 TED-347 TED-347 is a potent, irreversible, covalent and allosteric inhibitor of the TEAD⋅Yap protein-protein interaction. TED-347 inhibits TEAD4⋅Yap1 protein-protein interaction with an apparent EC50 of 5.9 μM.
Pediatr Blood Cancer, 2022, e29705
S9735 MGH-CP1 MGH-CP1 is a potent and selective inhibitor of transcriptional enhanced associate domain (TEAD) palmitoylation. MGH-CP1 exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro with IC50 of 710 nM and 672 nM, respectively.
S1786 Verteporfin (CL 318952) Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Nat Commun, 2022, 13(1):3117
Nat Commun, 2022, 13(1):50
J Pathol, 2022, 10.1002/path.5910
S8164 YAP-TEAD Inhibitor 1 (Peptide 17) YAP-TEAD Inhibitor 1 (Peptide 17) is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.
PLoS One, 2022, 17(4):e0266143
Research (Wash D C), 2022, 2022:9825916
Cancer Res, 2021, 81(22):5652-5665
S8554 Super-TDU Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.
Nat Commun, 2022, 13(1):3117
Int J Mol Med, 2022, 49(6)84
J Exp Clin Cancer Res, 2021, 40(1):23
S8661 CA3 (CIL56) CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS).
Cell Rep, 2022, 38(7):110390
Sci Rep, 2022, 12(1):45
Int J Ophthalmol, 2022, 15(5):701-710
S8950 MYF-01-37 MYF-01-37 is a novel covalent inhibitor of TEAD targeting Cys380 when incubated with the TEAD2 protein.
S8951 TED-347 TED-347 is a potent, irreversible, covalent and allosteric inhibitor of the TEAD⋅Yap protein-protein interaction. TED-347 inhibits TEAD4⋅Yap1 protein-protein interaction with an apparent EC50 of 5.9 μM.
Pediatr Blood Cancer, 2022, e29705
S9735 MGH-CP1 MGH-CP1 is a potent and selective inhibitor of transcriptional enhanced associate domain (TEAD) palmitoylation. MGH-CP1 exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro with IC50 of 710 nM and 672 nM, respectively.
Tags: TEAD inhibitor|TEAD agonist|TEAD activator|TEAD inducer|TEAD antagonist|TEAD signaling pathway|TEAD assay kit